1 in 3 New Buprenorphine Prescriptions Went Unfilled in 2024

For anyone planning what happens after opioid detox, a study published August 4 in JAMA Network Open identifies a failure point that sits outside the clinic entirely.

Medication-assisted treatment only works if the medication reaches the patient, and a growing share of first buprenorphine prescriptions never get dispensed at all.

Researchers analyzed what happens between a prescription being written and a patient actually walking out with it. The share that went unfilled rose from 19% in 2020 to 37% in 2024.

Why This Gap Matters After Detox

Withdrawal management is not treatment on its own, and the days immediately after detox are the most dangerous stretch in the whole process. Tolerance drops sharply during withdrawal.

If someone returns to their previous dose after that drop, the overdose risk is substantially higher than it was before they stopped. Buprenorphine is the main tool for closing that window. It suppresses withdrawal, reduces cravings, and occupies opioid receptors strongly enough to blunt the effect of other opioids.

Opioid agonist treatment is associated with reduced all-cause mortality in people with opioid dependence. That’s why continuity from detox into medication matters more than almost any other handoff in addiction care.

A prescription that is never filled breaks that handoff at the last possible moment, after the clinical decision has already been made correctly.

What the Study Found

The analysis was led by Xinyi Jiang of the Division of Overdose Prevention at the Centers for Disease Control and Prevention, with colleagues. It used deidentified electronic health records linked to administrative claims from the Optum Labs Data Warehouse, covering commercial and Medicare Advantage enrollees.

Researchers identified 1,428 adults who received a first buprenorphine prescription for opioid use disorder between January 2020 and September 2024 and checked whether it was dispensed within 30 days. Overall, 369 patients, or 25.8%, had a first prescription that was never filled.

The trend over time was the headline finding. Abandonment climbed steadily across the study period, from 19% of first prescriptions in 2020 to 37% in 2024, a statistically significant increase. Authors describe this as a lost opportunity to start and hold onto treatment.

Prior research had found that 32% of buprenorphine prescriptions written between 2015 and 2019 were not dispensed. So, experts have known about this problem and it appears to be worsening rather than a new one.

Cost and Coverage Barriers at the Pharmacy Counter

The patient characteristics associated with abandonment point more toward benefit design than toward motivation. Patients whose prescriptions went unfilled had higher pharmacy deductibles, averaging $483.80 compared with $296.40 among those who filled.

They were more likely to hold commercial insurance rather than Medicare Advantage, at 51.8% versus 29.4%. Notably, tier-2 retail pharmacy copays showed no statistically significant difference between the two groups.

That combination suggests the barrier is the deductible a patient has to clear before coverage begins, not the copay itself. Hispanic patients had a higher rate of abandonment, 10.6% compared with 4.8% among those who filled.

The authors suggest language barriers and pharmacy-level access may contribute, citing research showing fewer retail pharmacies in Hispanic and Black neighborhoods. They note this alongside rising overdose death rates among Hispanic populations. The team didn’t find statistically significant differences by sex or race.

Patients who did fill their prescriptions had greater likelihood to have a documented opioid use disorder or overdose, another substance use disorder, or a mental health diagnosis in the prior six months. In other words, prescriptions written for patients already engaged with the treatment system had a higher chance of being picked up.

Distinguishing Evidence from Shortcuts

It is worth naming what this study is not about. Buprenorphine and methadone are FDA-approved medications with a substantial evidence base behind them.

Rapid or ultra-rapid detox procedures, at-home tapering kits, and supplement regimens marketed as opioid detox do not carry comparable evidence and can be dangerous.

The problem this research describes is not that the evidence-based option failed. Rather, doctors prescribed the evidence-based option, but it did not reach the patient.

What the Study Cannot Tell Us

Authors directly note about the limits, and a few deserve emphasis. Thet cover only commercial and Medicare Advantage enrollees, so it does not describe Medicaid patients, the uninsured, or people treated in opioid treatment programs.

The cohort skews notably older, with a mean age of 56.6 years and about two-thirds on Medicare Advantage, which does not representat the broader population starting buprenorphine.

The data also cannot separate prescriptions a patient chose not to fill from prescriptions rejected by an insurer or a pharmacy. Both count as abandonment here, and they call for very different fixes.

Some prescriptions paid in cash, through assistance programs, or through insurance not captured in the linked claims may have been misclassified as unfilled. The sample of 1,428 is relatively small for a claims analysis.

Finding Medical Detox and Medication-Assisted Treatment

If you or someone you love is planning a detox, a few questions are worth asking before admission. Ask whether the program starts buprenorphine or methadone on site rather than at discharge.

Inquire who arranges the first outpatient appointment and when they schedule it. Look into what the program does if a pharmacy rejects the prescription. Ask about your pharmacy deductible specifically, not just your copay, since that is the cost that appears to matter most here.

If a patient refuses a prescription or can’t afford it at the counter, call the prescriber before leaving. Manufacturer assistance programs, 340B pharmacies, federally qualified health centers, and opioid treatment programs are all routes to the same medication.

Never attempt alcohol or benzodiazepine detox without medical supervision, as withdrawal from either can be life-threatening. Detox.com can help you find medically supervised detox programs and providers offering medication-assisted treatment. Call 800-996-6135(Sponsored) to receive confidential support today.